Happy Halloween! Endovascular Engineering Ladera Medical
Inventure Group
Medical Equipment Manufacturing
Menlo Park, California 673 followers
A medical technology accelerator focused on delivering novel product solutions to unmet and underserved clinical needs.
About us
A medical device incubator uniquely dedicated to engineering excellence and operational execution. Inventure Group places engineering at the core of its mission to advance early-stage medical innovation. By providing an ecosystem rich in cross-functional expertise, cutting-edge infrastructure, and valuable resources, Inventure Group drives the creation and development of medical devices from concept to approval.
- Industry
- Medical Equipment Manufacturing
- Company size
- 2-10 employees
- Headquarters
- Menlo Park, California
- Type
- Privately Held
Locations
-
Primary
Get directions
3905 Bohannon Dr
Suite F
Menlo Park, California 94025, US
Employees at Inventure Group
Updates
-
Proud to see one of our portfolio companies Endovascular Engineering strengthen its executive team! Congratulations to Dan Rose on joining as the new CEO. His expertise will be instrumental in leading the company towards the goal of making the Hēlo™ PE Thrombectomy System the preferred option for the treatment of pulmonary embolism (#PE). Exciting to witness E2 leading the way! NOTE: Hēlo PE for investigational use only.
We are excited to welcome Dan Rose as our new Chief Executive Officer, while co-founder Mike Rosenthal transitions to the role of Chief Operating Officer. These changes in our leadership team position our organization for the next phase of transformative growth as we advance through the #ENGULF pivotal trial and pursue 510(k) clearance. Read our press release: https://prn.to/4fQjkeg #endovascular #thrombectomy
-
-
We applaud Endovascular Engineering for achieving such a significant milestone with the positive results from the #ENGULF Feasibility Trial for the Hēlo™ PE Thrombectomy System. The clinical evidence gathered underscores the commitment to innovation and patient care, setting a new standard in #endovascular care. With more clinical evidence than any other emerging company in this field, E2 leads the way in #PE treatment innovation.
Exciting Announcement! We're delighted to share the positive outcomes from our ENGULF Feasibility Trial featuring the groundbreaking Hēlo™ PE Thrombectomy System for pulmonary embolism treatment. “The clinical evidence demonstrated in the ENGULF feasibility study supports the utility of the Hēlo's novel features," said Dr. Jay Giri, Director of Cardiovascular Catheterization Laboratories at the Hospital of the University of Pennsylvania. To learn more about the study results, visit https://lnkd.in/gWqENVKH Note: Hēlo PE for investigational use only. #Hēlo #HēloThrombectomySystem #ENGULF
-
-
Inventure Group reposted this
Join us tomorrow during #SCAI2024 to hear Dr. Taisei Kobayashi present both in the morning and afternoon. The morning workshop will feature E2’s Hēlo™ Thrombectomy System as a novel interventional device for the treatment of #PE. In the afternoon, Dr. Taisei Kobayashi will present safety and feasibility of E2’s Hēlo™️ Thrombectomy System for the treatment of #PE from the #ENGULF trial. Note: Hēlo PE for investigational use only.
-
-
At Inventure Group, we've been privileged to witness the Endovascular Engineering team's dedication, innovation, and steadfast commitment to revolutionizing #endovascular care. We're eager to see the transformative impact of the Hēlo™ Thrombectomy System on patient care in the venous thromboembolism (VTE) sector. #LSIUSA24 #LSIAlumni #Innovation
Last week, our CEO, Mike Rosenthal, took the stage at #LSIUSA24 to present the innovative Hēlo™ Thrombectomy System by Endovascular Engineering. The Hēlo™ System aims to revolutionize the treatment of venous thromboembolism (VTE). Addressing the large and underpenetrated #vte market, Hēlo™ introduces advanced solutions to address this market with superior navigation, effective clot removal, and enhanced procedural efficiency. We are proud to lead the fight against VTE and are making strides toward safer, more effective patient care as we reimagine #endovascular treatment. Note: Hēlo PE for investigational use only.
-
-
Endovascular Engineering continuing to do great things with a meaningful product supported by a stellar team!
Experienced in building medical device companies /Medical Device executive/product launch/sales scale-up
Congratulations, William Harris, Chris LeSar, MD., FACS and the Vascular Institute of Chattanooga team on the successful completion of their fourth venous thrombectomy case using the Hēlo G1 thrombectomy system! This innovative technology helps remove dangerous blood clots without the use of thrombolytic drugs, offering patients another exciting mechanical treatment option for venous clots. Endovascular Engineering Society for Vascular Surgery American Venous Forum | AVF Kelly Little Mike Rosenthal Scott Baron Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM Cordis Inventure Group Sante Health Ventures II LP #vascularmedicine #thrombectomy #bloodclots #vascularsurgery #interventionalcardiology #interventionalradiology #innovation
-
-
Major progress for Endovascular Engineering. Thank you to all the employees and clinicians behind this amazing technology.
Congratulations to Endovascular Engineering on receiving IDE approval to start the ENGULF Pivotal trial! Endovascular Engineering (E2) focuses on the development and deployment of groundbreaking clot removal technologies that target venous thromboembolism (VTE). Today they received Investigational Device Exemption (IDE) from the FDA to begin the ENGULF pivotal trial in the US. This will allow the company to evaluate the safety and effectiveness of its Hēlo Thrombectomy System in treating pulmonary embolism (PE) - marking a significant step forward in the development of innovative clot removal technologies. E2 is part of our third fund and we were a co-lead in the Series A funding round. More details in the press release below! https://lnkd.in/eAUyqQkm
-
2023 has been an exciting year for Inventure and the portfolio companies. For our holiday event, employees wanted to give back to the community. So, we partnered with a local elementary school with underserved students and fulfilled the wish lists of over 40 children. We also got the chance to build bicycles that the school could give to families in need. Wishing everyone a happy and health holiday season.
-